Allogene Therapeutics Q1 Net Loss Narrows

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

In 2025, President Trump ordered the development of Golden Dome, a missile defense system with space-based interceptors. The Pentagon awarded $3.2B to 12 companies, including Booz Allen, to develop boost-phase defenses. Booz Allen proposed 'Brilliant Swarms,' a system of 2,000 small interceptor-satellites costing $25B to deploy. The system aims to intercept missiles before they release warheads and decoys, addressing threats from Russia and China. Critics argue such systems are costly and may no

BofA Securities raised GitLab's price target to $54 from $45, keeping a neutral rating. Morgan Stanley also increased its target to $57 from $30, maintaining an equal weight rating. GitLab's stock is currently trading at $45.09, down 3.12% on the day.

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin